Management Team


Leah Makley


Leah received a Ph.D. in medicinal chemistry from the University of Michigan in 2014, and a B.S. in biochemistry from the University of Dayton in 2009. She developed ViewPoint's flagship technology as a graduate student in Jason's lab and cofounded the company. While at the University of Michigan, she participated in the Pharmacological Sciences Training Program, was a fellow of the American Foundation for Pharmaceutical Education, and was named an Alzheimer's Drug Discovery Foundation Young Investigator. Leah has expertise in biophysical methods, protein biochemistry, high-throughput screening, and medicinal chemistry. 

ViewPoint_finals_1-12 (1) CROPPED.jpg



Bob joined Viewpoint Therapeutics as Chief Medical Officer in May 2018. He is a board-certified ophthalmologist who comes to Viewpoint from Genentech, Novartis, GSK, Carl Zeiss Meditec, and most recently Apellis Pharmaceuticals. He has been involved in Phase 1-3 development of numerous drugs, including Lucentis, Simbrinza, Pazeo, and most recently pegcetacoplan (APL-2). Bob completed his residency in ophthalmology at the University of California, San Francisco (UCSF), post-doctoral training in molecular biology of lens crystallins at the NIH, and retina fellowship training at Moorfields Eye Hospital in London. He received his undergraduate and MD degrees from Brown University and an MBA from UC Berkeley. He is currently an Associate Clinical Professor of Ophthalmology at UCSF, where he continues to see patients.


ViewPoint_finals_1-23 (1) CROPPED.jpg

Brian Connolly


Brian is currently Senior Director of Operations at ViewPoint Therapeutics and responsible for overseeing project management, business development, financing, manufacturing, quality, and regulatory operations. Brian joined ViewPoint in October 2018 as Senior Director of Project Management. He has over 14 years of experience in drug development, clinical/commercial manufacturing, team leadership, and project & portfolio management. Most recently, Brian contributed to the NDA approval and commercial launch of ZEMDRI (plazomicin) at Achaogen with responsibilities in team leadership, project management, and commercial manufacturing operations. Prior to Achaogen, Brian was at Genentech for over 12 years where he was responsible for the global Roche/Genentech CMC portfolio budget planning process and contributed to the development and commercialization of Avastin (bevacizumab), Ocrevus (ocrelizumab) Subcutaneous Delivery, Ranibizumab Sustained Delivery, Ranibizumab Port Delivery System, Mosunetuzumab, BFCR4350A, and other early development small molecule and large molecule NMEs in various roles of increasing leadership over the years. Brian holds a B.S. in Bioengineering from the University of California, San Diego.

ViewPoint_finals_1-25 (1).jpg

Mike Lopez


Mike joined ViewPoint as Associate Director of Medicinal Chemistry in January of 2019. Previously he was a research scientist at Achaogen where he participated in early stage antibiotic drug discovery programs. While at Achaogen, Mike led efforts to leverage naturally- occurring antibiotic biosynthetic pathways to enable medicinal chemistry projects.  Prior to Achaogen, Mike was a postdoctoral research fellow in the Department of Infectious Disease at Genentech where he studied the biochemical mechanisms by which Staphylococcus aureus senses and responds to the host environment. Mike holds a B.S in chemistry from UC Berkeley and completed his PhD in Chemistry and Chemical Biology at UC San Francisco.

ViewPoint_finals_1-10 (1).jpg

Noelynn Oliver


Noelynn joined ViewPoint Therapeutics in December 2018 as Sr. Director, Biology. Her work in biotech and pharma has involved new target discovery, lead optimization, indication selection, IND enabling studies and clinical trial design. Previously at Boehringer Ingelheim and FibroGen, she led discovery research groups and external collaborations to advance therapies for cardiovascular, pulmonary, kidney and liver diseases, and regenerative medicine. Her teams developed disease modeling assays that emphasize organ function for target validation, mechanistic testing and biomarker discovery. She obtained a BA in biological sciences from Cornell University, a Ph. D. in genetics from Stanford University and conducted postdoctoral studies in molecular biology at the Salk Institute.

ViewPoint_finals_1-3 (1).jpg

Bryan Dunyak


Bryan joined ViewPoint Therapeutics in July of 2017 and is currently Associate Director of Research. He completed postdoctoral training at University of California, San Francisco in the Institute of Neurodegenerative Diseases, where he studied diseases of protein misfolding and the biochemistry of chaperone proteins. Bryan received a Ph.D. in biological chemistry from the University of Michigan in 2016 for his work on peptidyl-prolyl isomerases as promising targets for natural product-inspired therapeutics and a B.S. in chemistry from Michigan State University. He has previously worked at Pfizer, where he gained experience in assay development, target identification, and high-throughput screening. Bryan has expertise in chemistry, biochemistry, chemical biology, and biophysics, with a focus on multidisciplinary drug discovery.


HAIgang Chen


Haigang Chen joined ViewPoint as the Director of Product Development and is responsible for overseeing the development of drug product, process optimization, production and clinical supply to support the ViewPoint portfolio.

For over a decade, Haigang held serval leadership roles at companies such as Bausch Health, Perrigo Company, Corcept Therapeutics, and Nanocopoeia Inc. One of Haigang’s strengths is the ability to enhance the bioavailability of ocular and oral products utilizing amorphous solid dispersion, lipidic and nanotechnologies.

Haigang holds a Ph.D. from University of the Pacific, and a B.S. in Chemistry from Tsinghua University.


ViewPoint is further supported by a team of consultants and contractors with deep expertise in medicinal chemistry, formulations, preclinical and clinical development, chemistry manufacturing, and regulatory affairs.